A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

NCT03474679 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft vs Host Disease

Interventions

DRUG: Ibrutinib

Sponsor

Janssen Pharmaceutical K.K.